Weina Han

Dr. Weina Han


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2018 in Chirality
Verified
Journal Article
Closed access
PDF file
TWTong Wu
Tong Wu
JZJiu‐Xin Zhu
Jiu‐Xin Zhu
QWQian Wei
Qian Wei
PLPing Li
Ping Li
LWLi‐Bo Wang
Li‐Bo Wang
WHWeina Han
Weina Han

1 January 2020 in Zeitschrift für Naturforschung C
Verified
Journal Article
Closed access
PDF file
WHWenxin Huang
Wenxin Huang
LSLiwen Sun
Liwen Sun
BWBaihui Wang
Baihui Wang
YMYan Ma
Yan Ma
DYDahong Yao
Dahong Yao
LWLibo Wang
Libo Wang
The overexpression of sialic acids and sialyltransferases (STs) during malignant transformation and progression could result in the aberrant sialylation of cancer cells. Therefore, interfering the sialic acid synthesis might be an effective pathway in cancer therapy. In this study, we assessed that the antitumor inhibitors of 20(S)-ginsenosides Rg3, 20(R)-ginsenosides Rg3, 20(S)-ginsenosides Rh2, and 20(R)-ginsenosides Rh2 could block the sialoglycans in liver cancer cells HepG2. The results showed that these four compounds could inhibit the expressions of the total and free sialic acid at different levels in HepG2, respectively; also, it showed dose dependence. In addition, the results of the enzyme-linked immunosorbent assay showed that the above four compounds can inhibit the expression of STs significantly. We also found that these compounds could mediate the block of sialylation of α2,3- and α2,6-linked sialic acids in HepG2 cells by flow cytometry. Meanwhile, the results of the molecular docking investigation showed that these compounds showed strong interaction with ST6GalI and ST3GalI. These results verified that the ginsenosides have a powerful inhibiting aberrant sialylation, and it laid a theoretical foundation for further research on the investigation of ginsenosides as the target inhibitors on STs.

1 April 2022 in Mini-Reviews in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
KWKexin Wang
Kexin Wang
YWYue Wang
Yue Wang
HZHualin Zhang
Hualin Zhang
XLXintong Li
Xintong Li
WHWeina Han
Weina Han
: Endogenous nitric oxide (NO) is an important effector molecule and signal transduction molecule, which participates in the regulation of multiple functions in organisms, involving a variety of physiological and pathological processes, especially playing a very important role in the cardiovascular, immune, and nervous systems. NO is a gaseous substance with a short half-life in the body and is unstable in aqueous solutions. Therefore, many researchers focus on the release and activity of NO donors and their derivatives. However, NO donors can release free NO or NO analogues under physiological conditions to meet the human need. NO donors can be coupled with the corresponding active basic nucleus, so that they have the biological activity derived from both the basic nucleus and the NO donors, thus performing better bioactivity. This paper reviewed the routes of synthesis and advance activities of NO donor derivatives.

20 April 2025 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
XWXutong Wang
Xutong Wang
YLYu Liu
Yu Liu
ZGZeyu Gao
Zeyu Gao
XFXiaodong Fang
Xiaodong Fang
KMKejing Ma
Kejing Ma
WHWeina Han
Weina Han

9 June 2025 in Bioorganic Chemistry
Verified
Journal Article
Closed access
ZGZeyu Gao
Zeyu Gao
XWXutong Wang
Xutong Wang
DLDong Li
Dong Li
SZShuoqi Zhao
Shuoqi Zhao
ZWZihan Wu
Zihan Wu
WHWeina Han
Weina Han

1 September 2020 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
DYDahong Yao
Dahong Yao
ARA. Ruhan
A. Ruhan
JJJin Jiang
Jin Jiang
JHJian Huang
Jian Huang
JWJinhui Wang
Jinhui Wang
WHWeina Han
Weina Han